Research Scientist I - Tumor Microenvironment
Gilead Sciences is continuing to hire for all open roles. Our interview process may be conducted virtually and some roles will be asked to temporarily work from home. Over the coming weeks and months, we will be implementing a phased approach to bringing employees back to site to ensure the health and safety of our teams.
For Current Gilead Employees and Contractors:
We are seeking an exceptional scientist to join the Oncology department at Gilead Sciences, Inc. Gilead is a world leader in antiviral research having developed small molecule compounds that have revolutionized the treatment of HIV, HCV, and HBV. Over the last 10 years, Gilead has significantly broadened its scope to encompass unmet medical needs in cancer and inflammation. Our research team is engaged in the discovery and development of novel therapeutics targeting the tumor microenvironment, with the goal of potentiating the anti-tumor immune response and synergizing with established and emerging immunotherapy approaches. The successful candidate will integrate into this team, leading and supporting biological investigation of new and established therapeutic targets. This position provides an exciting opportunity to have high-impact participation in the growth of a new research area within the established and highly collaborative oncology research group at Gilead. Essential Duties and Job Responsibilities:
Knowledge, Experience and Skills:
- Drive discovery and translational research aimed at identifying and advancing novel therapeutics
- Identify key scientific questions, design hypothesis-based experiments and analyze and interpret data to support initiation and/or advancement of therapeutic programs.
- Engage in cross-functional collaborations across Gilead's research organization (e.g. Medicinal Chemistry, Protein Therapeutics, High-Throughput Biology, Bioinformatics, Clinical Oncology, Biomarkers) to effectively develop new drugs.
- Participate in established external collaborations and bring outside expertise to Gilead by identifying and engaging new academic collaborators.
- May participate in evaluation of external licensing opportunities.
- Participate as an engaged member of the highly interactive Oncology department. Present research findings and recommendations to senior staff and contribute to preparation of research reports, manuscripts, INDs, and patent filings.
- May manage Research Associates or direct members of project teams in the initiation and execution of laboratory experimentation.
- PhD or equivalent degree and 3+ years of relevant post-graduate experience, preferably in drug development.
- Strong background in immunology and flow-cytometry-based assay development and experience running functional immune cell activation assays is desired.
- Fluency in the use of molecular techniques to evaluate signaling networks and cytokine/chemokine expression (eg. western blot, ELISA, proteomics as well as siRNA/shRNA, CRISPR and gene expression analysis).
- Candidates with experience in tumor vasculature, the formation and maintenance of secondary and tertiary lymphoid organs/structures, activated myofibroblast signaling mechanisms, and/or immune-stroma-tumor co-culture systems are highly encouraged to apply
- A working knowledge of the design and execution of in vivo animal model studies is a plus
- Strong communication skills required, with an ability to communicate and scientifically engage individuals across a large breadth of levels and translate ideas and data into concise written and verbal communications.
For jobs in the United States:
As an equal opportunity employer, Gilead Sciences Inc. is committed to a diverse workforce. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job related characteristics or other prohibited grounds specified in applicable federal, state and local laws. In order to ensure reasonable accommodation for individuals protected by Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veterans' Readjustment Act of 1974, and Title I of the Americans with Disabilities Act of 1990, applicants who require accommodation in the job application process may contact firstname.lastname@example.org for assistance. Following extensive monitoring, research, consideration of business implications and advice from internal and external experts, Gilead has made the decision to require all U.S. employees and contractors to receive the COVID-19 vaccines as a condition of employment. "Full vaccination" is defined as two weeks after both doses of a two-dose vaccine or two weeks since a single-dose vaccine has been administered. Anyone unable to be vaccinated, either because of a sincerely held religious belief or a medical condition or disability that prevents them from being vaccinated, can request a reasonable accommodation.
For more information about equal employment opportunity protections, please view the ‘EEO is the Law' poster.
Our environment respects individual differences and recognizes each employee as an integral member of our company. Our workforce reflects these values and celebrates the individuals who make up our growing team.
Gilead provides a work environment free of harassment and prohibited conduct. We promote and support individual differences and diversity of thoughts and opinion.
For Current Gilead Employees and Contractors:
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Following extensive monitoring, research, consideration of business implications and advice from internal and external experts, Gilead has made the decision to require all U.S. employees and contractors to be fully vaccinated against COVID-19 as a condition of employment. The health of our employees, contractors, their loved ones, our partners and the communities and people we serve is a top priority. Vaccination is the most effective way currently available to deliver on that priority. The purpose of the vaccination requirement is to minimize the spread of COVID-19 in the workplace and support the health and safety of our communities. A person is considered fully vaccinated two weeks after the second dose of a two-dose vaccine or two weeks after a single-dose vaccine has been administered. Anyone unable to be vaccinated, either because of a sincerely held religious belief or a medical condition or disability that prevents them from being vaccinated, can request an accommodation.
Research Scientist - Immuno-Oncology
Research Scientist I, HBV Cure
Research Scientist/Senior Research Scientist - HIV Virology, Biology
Senior Research Scientist I, Drug Metabolism
Sr. Research Scientist - Immuno-Oncology